Overview

VenoVision is on a mission to transform cardiac care for millions of heart failure and at-risk patients. VenoVision non-invasively delivers cardiac insights from the medical guidelines, previously limited to in-hospital catheterization. VenoVision is a thermal imaging-based biosensing device and hemodynamic monitoring platform for the entire continuum of care. VenoVision not only enables spotting deterioration, but also provides the cardiological feedback needed to adjust therapy in time to improve patient outcomes, lower length of stay and reduce (re)hospitalizations. VenoVision uniquely overcomes the challenges of monitoring obese cardiovascular patients. We’re proud to be a Delaware C-Corp with Israeli origins! VenoVision was conceptualized in the Hebrew University of Jerusalem’s BioDesign Program and carried out its proof-of-concept clinical trial at Shaare Zedek Medical Center. It is a 2x alum of MassChallenge (Israel 2021 & HealthTech Sprint USA 2023) and is a Health Wildcatters accelerator (Dallas, Texas) 2022 portfolio company.